about
Pharmacokinetics in drug discoverySafety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsA phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerSunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice.Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group.Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.Effect of food on the bioavailability of palbociclib.Effect of axitinib on the QT interval in healthy volunteers.Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells.Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance.Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.Pharmacokinetics of single-agent axitinib across multiple solid tumor types.A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.Intrinsic absolute bioavailability prediction in rats based on in situ absorption rate constants and/or in vitro partition coefficients: 6-fluoroquinolones.A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in studyPharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab OzogamicinPopulation pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
P50
Q28236553-F046FAF6-4CB5-44D9-9B6A-FAEA17034C98Q33385313-8A9CE506-4A00-45BD-BBCF-A4A3C316BEC2Q33389519-B5D45A05-587B-44FB-A14C-5DA6FE0B2522Q33393174-27F35A36-0B9A-4C2E-B0CD-E050851948D4Q33397590-89AAA2E6-99C6-4B01-9B3F-85D7A92E0C83Q33406542-6B862A4B-0C0A-4C36-B4D0-ACFAC185C6A3Q33409913-25AC9E22-4BBC-48DB-89D6-590E36775418Q34180815-FDE3E450-0B1E-4D8F-A209-274E9429C106Q36236463-D8328891-FBEE-4115-9117-614A8BDDEA3AQ36470125-DA12B0B3-9755-4592-B999-8301D1197444Q37659109-16D7020F-66B4-435A-8B98-19AB7211A9F3Q38720418-809EBC15-2425-4854-97B4-7CBC63F8AF11Q38728850-2E351F31-7E5E-40B0-A82C-55A637306B08Q38958668-9D725C66-7889-4B9D-A14A-9D2F13A30029Q41582221-F7678F1E-85A0-419B-A052-3AF6898D1663Q42481542-C80BC7BC-4456-42B1-9E0D-0AFF4DA5A4E7Q43147962-121D12DC-2604-468F-A2FB-DEE071D2B089Q44108202-7B6F1E40-5976-4F6D-8CB7-9336EE9B7BD4Q44282851-B5D7DBFA-E465-4999-9546-21FDEF0CB995Q44982199-DD9C7127-CEF9-446E-89DD-E68A34D316C0Q46091244-835D51A3-D39F-4457-9D78-9C7FCB620CD0Q48512373-ABDDBFEF-CACC-4E5C-96DC-A7E3608C82CDQ51299907-4B529221-7A8A-42DD-8585-354393A5C2E2Q52073169-DAF950B4-DC74-4E62-AED5-45AFFB638FC4Q54600318-6C29E165-1B8F-4292-A2F0-6E2066A7CDD6Q84487806-AB36F9B4-92AA-4358-BFC1-5D6E491B8954Q91880326-822E6FEA-0F7F-4094-9C84-5126D9581643Q92288544-0067A978-D048-43C4-90ED-8EF2B5D55A23
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ana Ruiz-Garcia
@ast
Ana Ruiz-Garcia
@en
Ana Ruiz-Garcia
@es
Ana Ruiz-Garcia
@nl
type
label
Ana Ruiz-Garcia
@ast
Ana Ruiz-Garcia
@en
Ana Ruiz-Garcia
@es
Ana Ruiz-Garcia
@nl
prefLabel
Ana Ruiz-Garcia
@ast
Ana Ruiz-Garcia
@en
Ana Ruiz-Garcia
@es
Ana Ruiz-Garcia
@nl
P106
P21
P31
P496
0000-0002-5462-3110